XML 28 R12.htm IDEA: XBRL DOCUMENT

EARNINGS (LOSS) PER SHARE

9 Months Ended

Sep. 30, 2025

EARNINGS (LOSS) PER SHARE

EARNINGS (LOSS) PER SHARE

NOTE 6 – EARNINGS (LOSS) PER SHARE

Basic and diluted earnings (loss) per share attributable to common stockholders were calculated as follows:


		Nine Months Ended September 30,							Three Months Ended September 30,
(In thousands, except share data)		2025			2024			2025			2024
Numerator:
Net income (loss)		$	(1,100)		$	(3,562)		$	2,355		$	3,236
Add:
Financial expenses of 2024 Notes*												(503)
Net income (loss) for diluted calculation		$	(1,100)		$	(3,562)		$	2,355		$	2,733
Denominator:
Weighted average shares of Common Stock outstanding for basic calculation			78,225,112			73,301,091			79,281,685			73,549,745
Weighted average dilutive effect of 2024 Notes												7,667,323
Weighted average dilutive effect of stock options and restricted stock									1,532,879
Weighted average shares of Common Stock outstanding for diluted calculation			78,225,112			73,301,091			80,814,564			81,217,068

* Financial expenses on 2024 Notes consists of add back of financial expense incurred during the period and inclusion of make-whole interest payments that will be incurred upon conversion.

Diluted earnings (loss) per share do not include 11,288,007 shares of Common Stock underlying outstanding stock options, unvested shares of restricted stock and warrants for the nine months ended September 30, 2025 because the effect would be anti-dilutive.

Diluted earnings (loss) per share do not include 3,745,682 shares of Common Stock underlying outstanding stock options and unvested shares of restricted stock for the three months ended September 30, 2025 because the effect would be anti-dilutive.

Diluted earnings (loss) per share do not include 30,515,287 shares of Common Stock underlying outstanding stock options, unvested shares of restricted stock, warrants and the 2024 Notes for the nine months ended September 30, 2024, and 20,173,438 shares of Common Stock underlying outstanding stock options, unvested shares of restricted stock and warrants for the three months ended September 30, 2024, because the effect would be anti-dilutive.